Abstract:
An organometallic compound represented by Formula 1:
M1(L1)n1(L2)n2 Formula 1
wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2,
wherein X1 is C or N; X2 is C or N; X3 is C or N; X4 is C or N; ring CY1 and ring CY2 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group; Z1 and Z2 are each independently —Si(Q1)(Q2)(Q3) or —Ge(Q1)(Q2)(Q3); a1 and a2 are each independently an integer from 0 to 10; a sum of a1 and a2 is 1 or greater; Y1 and Y2 are each independently O, S, Se, N(R51), B(R52), C(R53)(R54), Si(R55)(R56), or Ge(R57)(R58); and the remaining substituent groups are as described herein.
Abstract:
An organometallic compound represented by Formula 1:
M1(L1)n1(L2)n2 Formula 1
wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2,
wherein ring CY1, ring CY2, ring CY4, R1, R2, R4, R31, R32, X1 to X4, Y1, Z1, Z2, a1, a2, b1, b2, b31, b32, and b4 in Formulae 1A and 1B are respectively as described herein, and * and *′ each indicate a binding site to M1.
Abstract:
An organometallic compound represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, in Formula 1, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein CY1 is a 6-membered N-containing heterocyclic group, a 6-membered N-containing heterocyclic group condensed with a C1-C30 carbocyclic group, or a 6-membered N-containing heterocyclic group condensed with a C5-C30 heterocyclic group, CY21 is a 5-membered carbocyclic group or a 5-membered heterocyclic group, X31 and X32 are each independently O or S, * and *′ each indicate a binding site to M1, and R10, R20 to R22, R31 to R37, b10, and b20 are as provided herein.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein, in Formulae 1, 1A, and 1B, X1 is C or N, X2 is C or N, CY1 and CY2 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, CY3 is a 6-membered N-containing heterocyclic group, a 6-membered N-containing heterocyclic group condensed with a C5-C30 carbocyclic group, or a 6-membered N-containing heterocyclic group condensed with a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, CY41 is a 5-membered carbocyclic group or a 5-membered heterocyclic group, * and *′ each represent a bonding site to M1, and wherein R10, R20 to R30, R40 to R42, and b10 to b40 are as provided herein.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, in Formula 1, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein X1, X2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, CY1, CY2, CY3, T1, T2, a1, a2, R10, R20, R30, b10, b20, and b30 are each as described herein.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, Ln1 is a ligand represented by Formula 1-1, Ln2 is a ligand represented by Formula 2-1 or Formula 2-2, n1 may be 1 or 2, and n2 may be 1 or 2, wherein the other substituents may be understood by referring to the descriptions thereof provided herein:
Abstract:
An organometallic compound represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B: wherein, in Formulae 1, 1A, and 1B, M1 is a transition metal, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 0, 1, or 2, n2 is 1, 2, or 3, a1 is 0, 1, 2, or 3, k1 is 1, 2, 3, 4, 5, 6, 7, or 8, b10 and b20 are each independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and * and *′ each represents a binding site to M1, and wherein CY1, CY2, X1, X2, Y1 to Y10, L1, Ar1, R1, R2, R10, and R20 are as provided herein.
Abstract:
An organometallic compound represented by Formula 1: M(L1)n1(L2)n2 Formula 1 wherein in Formula 1, M, L1, L2, n1, and n2 are the same as described in the specification.
Abstract:
An organometallic compound represented by Formula 1:
M1(L1)n1(L2)n2 Formula 1
wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, and n1 and n2 are each independently 1 or 2:
with the proviso that i) X43 is C linked to Y2 in Formula 2 and X44 is C linked to Y3 in Formula 2; ii) X44 is C linked to Y2 in Formula 2 and X45 is C linked to Y3 in Formula 2; or iii) X45 is C linked to Y2 in Formula 2 and X46 is C linked to Y5 in Formula 2; wherein the remaining substituent groups of Formulae 1A, 1B, and 2 are as provided herein.
Abstract:
An organometallic compound, represented by Formula 1: M1(Ln1)n1(Ln2)n2 Formula 1 wherein Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein ring CY21 is a 5-membered carbocyclic group or a 5-membered heterocyclic group, X31 and X32 are each independently O or S, b20 is an integer from 0 to 6, R11 to R18, R20 to R22, and R31 to R37 are as defined herein, and * and *′ each indicates a binding site to M1.